Two Ways of Seeing — Why Reviewers Need Both the Rule-Eye and the Recipient-Eye

Asking only "does this material comply with the text of the guidelines?" is half a review. Materials that satisfy every clause on paper while causing physicians to misread evidence — and patients to miss appropriate treatment — appear repeatedly across seven years of regulatory monitoring records. A second question is required: "What will happen to the person who receives this information?" Only when that question runs alongside the first does compliance checking become a practice that prevents real harm.

So What / So Why — The Core of Each Perspective

The rule-eye maps a material against the principles of the Guidelines on Promotional Activities for Prescription Drugs: scientific basis, citation accuracy, validity of comparative claims, completeness of safety information. It finds problems, names them, and grounds a request for revision. Without it, review collapses into personal impression.

But certain failures stay outside the rule-eye's range. What seven years of monitoring has shown repeatedly is a pattern where the creator never registers that a violation occurred — because the internal logic held together. "The numbers themselves were accurate." "No one asked, so I didn't say." "I matched the physician's interests." Under motivated reasoning, favorable data reads as "key information" and unfavorable data reads as "not relevant in this context." A person can hold the rule-eye and still not apply it to their own work.

The recipient-eye covers that blind spot. When the audience is a physician: "After hearing this explanation, what will the physician believe, and what prescription will follow?" When the audience is a patient: "After receiving this material, how will the patient understand their condition and their drug?" If the rule-eye draws the outline of a deviation, the recipient-eye measures its weight. Both are needed before review moves from "formal check" to "work that prevents harm."

Inside Each Perspective — What / Where / Why / How

What (what each eye looks at)
Data citation context, completeness of safety information, the balance between efficacy and safety claims, the basis for comparative language, the reading level of patient-facing materials. The rule-eye asks "which clause does this violate?" The recipient-eye asks "what will the reader believe?" Both look at the same material; the direction of the question reverses.

Where (the settings this applies to)
Hospital meeting slides, product brochures, videos and roundtable articles on HCP-facing information sites, MR verbal explanations, patient medication support tools. The medium does not matter. Verbal explanations leave no paper trail, but what a physician understands from them shapes prescribing decisions with the same force as a printed material.

Why (why both are necessary)
The rule-eye alone passes materials that are "technically lawful." The trial data figures are accurate; the citations are correct. But when baseline differences between patient groups are omitted, the receiving physician draws a completely different conclusion. The recipient-eye alone leaves a subjective sense that "something is wrong" without the language to justify a correction. The rule-eye supplies the grounds; the recipient-eye supplies the meaning.

How (putting it into practice)
Run two questions against each expression in the material in parallel. First: "Under which principle of the Guidelines on Promotional Activities does this expression create a problem?" Second: "What will the physician who receives this information believe, and which prescription will the patient receive?" When one question flags something, use the other to gauge severity. That back-and-forth is what allows a single review to achieve both formal compliance and harm prevention.

Entering the Other Perspective — Standing in That Position

Imagine a hospital meeting for an oncology drug. A representative advances a slide showing response-rate data from a clinical trial enrolling patients with resistance to first-line treatment. The slide compares all patients with Japanese patients, and the representative explains: "Response rates are higher in Japanese patients." The graph comes from a real trial. The numbers are accurate. The physician believes the explanation and chooses a prescription.

Now stand in the patient's position. After a prior regimen that did not work, you were referred to a treatment that your physician described as having better response rates in Japanese patients. You tolerate adverse effects and continue treatment. The expected response does not come. Your family remembers being told the drug works better in Japanese patients.

What becomes clear afterward: the difference shown in that graph was driven largely by differences in first-line treatment history between Japanese patients and the overall population. It was not a difference in drug effect. It was a difference in prior treatment. That distinction was never explained.

Standing in this position is not sentiment. It is the concrete exercise of tracing the path — what information a physician acts on, how a patient enters treatment on the strength of that information. Review work is the work of keeping errors out of that path. Before categorizing the violation or locating the relevant clause, the habit of asking "who will experience what outcome" sharpens the eye that reads materials.

Learning from Past Failures — Reading Documented Deviations Through Both Eyes

The 2019 report from Japan's pharmaceutical promotional monitoring program contains incidents that show exactly why both perspectives are required.

Incident 1: "Higher Efficacy in Japanese Patients" — Oncology Drug / Hospital Meeting Slides (published 2019)

Slides shown at a hospital meeting presented response-rate data from a clinical trial conducted in patients resistant to first-line treatment. The data compared all patients with Japanese patients, and the representative explained that response rates were higher in Japanese patients. According to the report, when a monitoring physician asked the representative directly, the representative acknowledged that "the difference in first-line treatment between all patients and Japanese patients may be the reason." A subsequent review of the trial report confirmed the scale of that difference: among all patients, Agent A accounted for roughly 50% of first-line treatment and Agent B for roughly 30%; among Japanese patients, Agent A accounted for roughly 20% and Agent B for roughly 70%. The report's conclusion is direct: "The representative explained that efficacy was higher in Japanese patients compared to all patients, without disclosing the difference in baseline conditions between the two groups."

Through the rule-eye: a deviation from the guideline principle requiring accurate information grounded in scientific evidence. Through the recipient-eye: a situation in which cancer patients and their families chose a treatment course on a false premise — that this drug works better in Japanese patients. There is a real possibility that some continued an ineffective treatment while believing the gap in prior therapy was a gap in drug effect.

The full analysis appears in "Anatomy of a Failure, Vol. 1 — Data Use and Modification That Risk Factual Misrepresentation."

Incident 2: "Transient, Tolerance Develops" — Analgesic / Product Video on HCP Information Site (published 2019)

A video hosted on a healthcare professional information site described adverse effects associated with high-dose use of an analgesic — hepatic injury and ALT elevation — as "transient, with tolerance developing." The video further cited the absence of correlation with a novel biomarker not yet applied in clinical practice as grounds for concluding that "ALT elevation does not directly reflect adverse effects." A review of the original literature found multiple cases in which marked ALT elevation led to patient withdrawal from treatment, making the characterization of the finding as "transient" difficult to sustain. The prescribing information included a warning specifically for high-dose use.

Through the rule-eye: a minimization of safety information that contradicts the prescribing information's documented adverse effects. Through the recipient-eye: patients receiving high-dose prescriptions who continued taking the drug under the false impression that hepatic-injury risk did not apply to them. Physicians who accepted the word "transient" may also have loosened monitoring as a result.

The full analysis appears in "Anatomy of a Failure, Vol. 6 — Emphasis on Efficacy Alone / Minimization of Safety Information."

What these two incidents share is that the numbers and the video were not fabricated. The deviation lives in the choices about what to show and what to leave out. Without the habit of asking what those choices do to the person on the receiving end, a material can pass every checklist item and still be one that should not have been passed. A map of the full incident set is available in "Introduction — The Full Picture of Documented Incidents."